Navigation Links
ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions
Date:4/1/2009

Testing Will Help Advance Technology to Find a Faster, More Accurate and Repeatable Method for Drug-Particle Sizing

PITTSBURGH, April 1 /PRNewswire/ -- ChemImage, (www.chemimage.com) today announces a strategic research partnership with Next Breath, LLC (www.nextbreath.net), a leading Contract Research Organization (CRO) to further validate ChemImage's Raman Chemical Imaging for bioequivalence applications for nasal spray suspensions.

Baltimore, MD-based Next Breath focuses on conducting in vitro bioequivalence testing for nasal sprays and chemistry, manufacturing and controls (CMC) testing for inhalation and nasal spray products, and is particularly interested in advancing the technology to find a faster and reproducible method for drug-particle sizing relative to bioequivalence studies for nasal spray suspensions.

"We are proud to partner with Next Breath because our goal at ChemImage is to validate our bioequivalence testing methodology," said Ryan Priore, Senior Scientist, ChemImage. "Pharmaceutical companies, particularly generic drug manufacturers focused on nasal spray suspensions, are looking to improve their time-to-market through the use of better imaging technology. The potential payoff is a faster, more accurate and safe way to bring the drug to market."

ChemImage, one of the world's leading chemical and biological imaging technology solutions companies, will be partnering with Next Breath to compare optical microscopy to Raman Chemical Imaging, specifically ChemImage's FALCON II(TM) Wide-Field Raman Chemical Imaging System.

The FALCON II enables drug manufacturers to perform chemical imaging of particles in droplets to distinguish the identity, particle size distribution of drug and other substances, aggregation, and the correlation about the location of the material in the formulation -- something drug makers have been unable to achieve in the past with standard optical microscopy as part of bioequivalence testing.

"Clearly, ChemImage has the potential to advance the ability of drug manufacturers to more accurately assess their risk when going into clinical trials by providing them with a more objective active ingredient particle size analysis between the Test and Reference Drug Product. Our work with ChemImage will help validate their Raman Chemical Imaging technology and services to perform in vitro drug particle size distribution measurements," said Julie Suman, President, Next Breath, LLC.

ChemImage's FALCON II is currently available for sale across international markets. ChemImage also offers imaging lab services for companies interested in expediting bioequivalence testing. The company expects the additional validation testing to be conducted in 2009 and 2010.

ChemImage and Next Breath will be attending the Nasal Drug Delivery Conference on April 1st - 2nd, 2009 in London.

About Next Breath

Next Breath is a contract services provider for pharmaceutical, biotech and medical device companies that bring new inhalation and nasal products to market. The company provides an array of in-vitro services, from pre-clinical formulation development to analytical testing in support of submissions to regulatory agencies. Its mission is to serve as an effective liaison between innovators of promising drug molecules and inventors of pulmonary and nasal drug delivery devices.

About ChemImage

ChemImage Corporation, headquartered in Pittsburgh, is a world leader in Chemical Imaging technologies; provides instrumentation, software, lab services and expert consulting to government, industrial and academic organizations. ChemImage offers these products and services for a range of applications including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. Its state-of-the-art Chemical Imaging technology can help to reveal critical chemical and biological information about processes, products and services.


'/>"/>
SOURCE ChemImage
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
2. Two nanostructures are better than one
3. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
4. NIST team develops novel method for nanostructured polymer thin films
5. Smart insulin nanostructures pass feasibility test, UT study reports
6. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
7. Researchers outline structure of largest nonvirus particle ever crystallized
8. CME LLC Restructures, Announces Its New Executive Management Team
9. Ames Laboratory researchers solve fuel-cell membrane structure conundrum
10. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
11. DRI Capital Launches Structured Finance Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... of medical marijuana products targeting the needs of consumers who are incorporating medical ... takes place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first ... accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):